粉尘螨滴剂治疗不同年龄变应性鼻炎患者的疗效评估

Efficacy of individualized sublingual immunotherapy with dermatophagoides farinae drops on patients with allergic rhinitis of different age groups

目的：探讨标准化粉尘螨滴剂个体化舌下特异性免疫治疗（SLIT）不同年龄变应性鼻炎（AR）患者的疗效。方法：以150例对粉尘螨过敏的AR患者为研究对象,均以标准化粉尘螨滴剂进行1.5~2.0年的SLIT,期间联合对症药物治疗。按就诊年龄将患者分为5组：第1组（5~7岁,17例）,第2组（〉7-12岁,38例）,第3组（〉12~18岁,31例）,第4组（19~40岁,38例）和第5组（〉40岁,26例）。评估不同年龄组患者的鼻部症状评分（TNSS）、体征评分和药物评分（TMS）的变化。对于其中SLIT不稳定或不理想的AR患者进行个体化剂量调整。结果：与治疗前相比,SLIT 0.5、1.0、1.5~2.0年后,不同年龄组AR患者的TNSS、TMS以及体征评分均显著改善（均P〈0.05）;TNSS、体征评分以及TMS组间均差异无统计学意义（均P〉0.05）。结论：采用标准化粉尘螨滴剂对不同年龄AR患者进行1.5~2.0年个体化SLIT均有疗效;不同年龄组患者取得的总体疗效未见明显差别。

Objective：To evaluate the efficacy of personal sublingual immunotherapy （SLIT） with dermato-to study the efficacy of dermatophagoides farinae drops for allergic rhinitis（AR） of different age groups. Method： The current study had analyzed the efficacy of SLIT in 150 patients with AR who were sensitized to house dust mites. All patients were treated with dermatophagoides farinae drops and combined with symptomatic treatment. The patients were divided into groups 1--5,group 1：17 patients （4--7 years old）, group 2：38 patients（〉7--12 years old）, group 3..31 patients（〉12--18 years old）, group 4.. 38 patients（〉18--40 years old） , group 5：26 patients （〉40--63 years old）. The total nasal symptom scores（TNSS）and total medicine scores（TMS） were re- corded at each visit. Before and after SLIT for 0.5 year, 1 year and 1.5 to 2.0 years, the TNSS and TMS of each patient were evaluated. The dosage adjustment of immunotherapy according to the patient＇s symptoms were per- formed. Result：The TNSS and TMS had continuously improved significantly after SLIT for half year, 1 year and 1.5 to 2.0 years in all groups as compared with baseline （P〈0.05）. There were no significant differences in the different age groups for TNSS and TMS during all time points. Conclusion： Individualized SLIT with dermatopha- goides farinae drops for 1.5-2.0 years is the most effective in the patients with allergic rhinitis of different age groups. And equivalent efficacy could be achieved for different age groups.